NeuroPace Förvaltning
Förvaltning kriterier kontrolleras 3/4
NeuroPace VD är Joel Becker, utsedd i Jul 2023, har en mandatperiod på 2.83 år. totala årliga ersättningen är $ 2.41M, bestående av 23.6% lön 76.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.29% av företagets aktier, värda $ 1.63M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.5 år respektive 4.8 år.
Viktig information
Joel Becker
Verkställande direktör
US$2.4m
Total ersättning
| VD-lön i procent | 23.56% |
| Anställning som VD | 2.8yrs |
| Ägande av VD | 0.3% |
| Ledningens genomsnittliga anställningstid | 1.5yrs |
| Styrelsens genomsnittliga mandatperiod | 4.8yrs |
Senaste uppdateringar av ledningen
Recent updates
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
Jan 09
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Nov 19NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Sep 19NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14NeuroPace: Volatile, Uncertain, But Promising
Jun 29Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Jun 19NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 13
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 07NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Jan 24After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
Dec 04Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
Nov 14Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Nov 07NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
Aug 03Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Apr 12NeuroPace: Picking Up The Pace
Feb 25Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Jan 22NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
Apr 17Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$568k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | -US$26m |
| Mar 31 2025 | n/a | n/a | -US$25m |
| Dec 31 2024 | US$3m | US$529k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$2m | US$248k | -US$33m |
Ersättning vs marknad: Joel s total kompensation ($USD 2.41M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.50M ).
Ersättning vs inkomst: Ersättningen från Joel har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Joel Becker (57 yo)
Mr. Joel D. Becker serves as CEO & Director of at NeuroPace, Inc. since July 10, 2023 and serves as its President. He had been President of Cardiac Rhythm Management & Neuromodulation at Integer Holdings C...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | 2.8yrs | US$2.41m | 0.29% $ 1.6m | |
| Chief Financial Officer | less than a year | US$1.88m | inga uppgifter | |
| Chief Medical Officer | 21.8yrs | US$1.03m | 0.14% $ 797.2k | |
| Advisor | less than a year | US$846.31k | 0.24% $ 1.3m | |
| Chief of Operations & Development | 2yrs | inga uppgifter | inga uppgifter | |
| Head of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| General Counsel & Corporate Secretary | 2.1yrs | inga uppgifter | inga uppgifter | |
| Vice President of Marketing | 1.3yrs | inga uppgifter | inga uppgifter | |
| Senior Vice President of Sales | 1yr | inga uppgifter | inga uppgifter | |
| Vice President of Human Resources | 1.6yrs | inga uppgifter | inga uppgifter | |
| VP & Controller | less than a year | inga uppgifter | inga uppgifter |
Erfaren ledning: NPCE s ledningsgrupp anses inte vara erfaren ( 1.5 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | 2.8yrs | US$2.41m | 0.29% $ 1.6m | |
| Independent Director | 29.3yrs | US$123.70k | 1.08% $ 6.2m | |
| Chairman of the Board | 28.5yrs | US$173.70k | 1.75% $ 10.0m | |
| Independent Director | 3.3yrs | US$126.20k | 0.044% $ 250.5k | |
| Independent Director | 1.3yrs | US$257.20k | 0% $ 0 | |
| Independent Director | 13.3yrs | US$136.20k | 0.12% $ 694.1k | |
| Board Observer | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 4.5yrs | US$138.70k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$138.70k | 0.056% $ 323.1k |
Erfaren styrelse: NPCE s styrelse anses vara erfaren ( 4.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 13:25 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
NeuroPace, Inc. bevakas av 11 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Polark | Baird |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Yi Chen | H.C. Wainwright & Co. |